Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.45 |
| ▸ | HTR2A | P28223 | 10/20 | 0.45 |
| ▸ | HTR2B | P41595 | 7/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2251133 | 0.87 | DRD1 (0.37) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL1049554 | 0.84 | FDPS (0.40) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL2257043 | 0.83 | HTR2C (0.42) | HTR2CHTR2AHTR2BKCNH2MEN1 | |
| SCHEMBL6907326 | 0.82 | TACR2 (0.43) | MEN1KMT2AEPAS1ALDH1A1HPGD | |
| SCHEMBL1052544 | 0.79 | EPAS1 (0.40) | MEN1KMT2AEPAS1ALDH1A1HTT | |
| SCHEMBL410179 | 0.77 | NPC1 (0.54) | MEN1KMT2AHPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL2253680 | 0.76 | ERN1 (0.42) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL14829980 | 0.73 | MAOB (0.51) | MEN1KMT2A | |
| SCHEMBL488952 | 0.72 | ALDH1A1 (0.42) | HTR2CHTR2AHTR2BMEN1KMT2A | |
| SCHEMBL9096100 | 0.72 | EPAS1 (0.39) | EPAS1ALDH1A1HPGDSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155747-B1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LTD (GB) | 2012-10-24 | — | — | EP | disclosed |
| EP-2155747-B1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LTD (GB) | 2012-10-24 | — | — | EP | disclosed |
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | GE HEALTHCARE LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
| EP-2155747-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | Acadia Pharmaceuticals Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008141249-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141249-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141239-A1 | IMIDAZOL [1,2-A] PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141239-A1 | IMIDAZOL [1,2-A] PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110206607-A1 | IMIDAZOL (1,2-A)PYRIDINES AND RELATED COMPOUNDS WITH ACTIVITY AT CANNABINOID CB2 RECEPTORS | CNR1, CNR2, GPR18 | HTR2C 164/4885HTR2A 690/4885HTR2B 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.